FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297147601> ?p ?o ?g. }

• W4297147601 abstract "Abstract Background Pharmacogenomic (PGx) testing has proved its utility and cost-effectiveness for some commonly prescribed cardiovascular disease (CVD) medications. In addition, PGx-guided dosing guidelines are now available for multiple CVD drugs, including clopidogrel, warfarin, and statins. The United Arab Emirates (UAE) population is diverse and multiethnic, with over 150 nationalities residing in the country. PGx-testing is not part of the standard of care in most global healthcare settings, including the UAE healthcare system. The first pharmacogenomic implementation clinical study in CVD has been approved recently, but multiple considerations needed evaluation before commencing. The current report appraises the PGx-clinical implementation procedure and the potential benefits of pursuing PGx-implementation initiatives in the UAE with global implications. Methods Patients prescribed one or more of the following drugs: clopidogrel, atorvastatin, rosuvastatin, and warfarin, were recruited. Genotyping selected genetic variants at genes interacting with the study drugs was performed by real-time PCR. Results For the current pilot study, 160 patients were recruited. The genotypes and inferred haplotypes, diplotypes, and predicted phenotypes revealed that 11.9% of the participants were poor CYP2C19 metabolizers, 35% intermediate metabolizers, 28.1% normal metabolizers, and 25% rapid or ultrarapid metabolizers. Notably, 46.9% of our cohort should receive a recommendation to avoid using clopidogrel or consider an alternative medication. Regarding warfarin, only 20% of the participants exhibited reference alleles at VKORC1 -1639G > A, CYP2C9 *2, and CYP2C9 *3, leaving 80% with alternative genotypes at any of the two genes that can be integrated into the warfarin dosing algorithms and can be used whenever the patient receives a warfarin prescription. For statins, 31.5% of patients carried at least one allele at the genotyped SLCO1B1 variant (rs4149056), increasing their risk of developing myopathy. 96% of our cohort received at least one PGx-generated clinical recommendation for the studied drugs. Conclusion The current pilot analysis verified the feasibility of PGx-testing and the unforeseen high frequencies of patients currently treated with suboptimal drug regimens, which may potentially benefit from PGx testing." @default.
• W4297147601 created "2022-09-27" @default.
• W4297147601 creator A5010263455 @default.
• W4297147601 creator A5012339555 @default.
• W4297147601 creator A5017517766 @default.
• W4297147601 creator A5021548441 @default.
• W4297147601 creator A5025869866 @default.
• W4297147601 creator A5034630738 @default.
• W4297147601 creator A5049057732 @default.
• W4297147601 creator A5067183244 @default.
• W4297147601 creator A5069604882 @default.
• W4297147601 creator A5079599019 @default.
• W4297147601 creator A5080029319 @default.
• W4297147601 creator A5082587097 @default.
• W4297147601 creator A5083002376 @default.
• W4297147601 creator A5089345606 @default.
• W4297147601 date "2022-09-25" @default.
• W4297147601 modified "2023-10-12" @default.
• W4297147601 title "Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates" @default.
• W4297147601 cites W1515782956 @default.
• W4297147601 cites W2153837110 @default.
• W4297147601 cites W2157839219 @default.
• W4297147601 cites W2288298157 @default.
• W4297147601 cites W2588108371 @default.
• W4297147601 cites W2791399109 @default.
• W4297147601 cites W2911243513 @default.
• W4297147601 cites W2936489929 @default.
• W4297147601 cites W2939903751 @default.
• W4297147601 cites W2947400776 @default.
• W4297147601 cites W2971992346 @default.
• W4297147601 cites W2988877141 @default.
• W4297147601 cites W2995227437 @default.
• W4297147601 cites W2999293106 @default.
• W4297147601 cites W3013131421 @default.
• W4297147601 cites W3080550893 @default.
• W4297147601 cites W3081295862 @default.
• W4297147601 cites W3093447658 @default.
• W4297147601 cites W3109947485 @default.
• W4297147601 cites W3110168772 @default.
• W4297147601 cites W3117218972 @default.
• W4297147601 cites W3124534407 @default.
• W4297147601 cites W3128287084 @default.
• W4297147601 cites W3157091748 @default.
• W4297147601 cites W3166824932 @default.
• W4297147601 cites W3199715121 @default.
• W4297147601 cites W3202340501 @default.
• W4297147601 cites W3209472386 @default.
• W4297147601 cites W4207040168 @default.
• W4297147601 cites W4210306444 @default.
• W4297147601 cites W4212817216 @default.
• W4297147601 cites W4213127162 @default.
• W4297147601 cites W4220783631 @default.
• W4297147601 cites W4226104943 @default.
• W4297147601 cites W4238924478 @default.
• W4297147601 doi "https://doi.org/10.1186/s40246-022-00417-9" @default.
• W4297147601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36154845" @default.
• W4297147601 hasPublicationYear "2022" @default.
• W4297147601 type Work @default.
• W4297147601 citedByCount "0" @default.
• W4297147601 crossrefType "journal-article" @default.
• W4297147601 hasAuthorship W4297147601A5010263455 @default.
• W4297147601 hasAuthorship W4297147601A5012339555 @default.
• W4297147601 hasAuthorship W4297147601A5017517766 @default.
• W4297147601 hasAuthorship W4297147601A5021548441 @default.
• W4297147601 hasAuthorship W4297147601A5025869866 @default.
• W4297147601 hasAuthorship W4297147601A5034630738 @default.
• W4297147601 hasAuthorship W4297147601A5049057732 @default.
• W4297147601 hasAuthorship W4297147601A5067183244 @default.
• W4297147601 hasAuthorship W4297147601A5069604882 @default.
• W4297147601 hasAuthorship W4297147601A5079599019 @default.
• W4297147601 hasAuthorship W4297147601A5080029319 @default.
• W4297147601 hasAuthorship W4297147601A5082587097 @default.
• W4297147601 hasAuthorship W4297147601A5083002376 @default.
• W4297147601 hasAuthorship W4297147601A5089345606 @default.
• W4297147601 hasBestOaLocation W42971476011 @default.
• W4297147601 hasConcept C104317684 @default.
• W4297147601 hasConcept C126322002 @default.
• W4297147601 hasConcept C135763542 @default.
• W4297147601 hasConcept C140840227 @default.
• W4297147601 hasConcept C142724271 @default.
• W4297147601 hasConcept C163763905 @default.
• W4297147601 hasConcept C170734499 @default.
• W4297147601 hasConcept C177713679 @default.
• W4297147601 hasConcept C2776301958 @default.
• W4297147601 hasConcept C2776318485 @default.
• W4297147601 hasConcept C2777288759 @default.
• W4297147601 hasConcept C2777628954 @default.
• W4297147601 hasConcept C2777849778 @default.
• W4297147601 hasConcept C2779161974 @default.
• W4297147601 hasConcept C2908647359 @default.
• W4297147601 hasConcept C3946865 @default.
• W4297147601 hasConcept C526171541 @default.
• W4297147601 hasConcept C54355233 @default.
• W4297147601 hasConcept C55775858 @default.
• W4297147601 hasConcept C62231903 @default.
• W4297147601 hasConcept C71924100 @default.
• W4297147601 hasConcept C86803240 @default.
• W4297147601 hasConcept C98274493 @default.
• W4297147601 hasConcept C99454951 @default.
• W4297147601 hasConceptScore W4297147601C104317684 @default.

• next